{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:50:48Z","timestamp":1790142648456,"version":"4.0.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016991","name":"Universidad de Guadalajara","doi-asserted-by":"publisher","award":["PIN-2025"],"award-info":[{"award-number":["PIN-2025"]}],"id":[{"id":"10.13039\/100016991","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Secretariat of Science Humanities Technology and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.msard.2025.106812","type":"journal-article","created":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:56:31Z","timestamp":1761519391000},"page":"106812","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["CAR T cells for multiple sclerosis: Engineering T cells to disrupt chronic B cell\u2013driven neuroinflammation"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7443-2514","authenticated-orcid":false,"given":"Daniel","family":"Ortu\u00f1o-Sahag\u00fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Hermosillo-Abundis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Paulina","family":"Reyes-Mata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d3scar","family":"Arias Carri\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2025.106812_bib0001","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-immunol-083122-044829","article-title":"Cell-directed therapy in autoimmunity","volume":"42","author":"Abeles","year":"2024","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.msard.2025.106812_bib0002","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1038\/s41467-020-19774-x","article-title":"Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia","volume":"11","author":"An","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.msard.2025.106812_bib0003","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.omtm.2021.10.010","article-title":"Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells","volume":"23","author":"Arjomandnejad","year":"2021","journal-title":"Molec. Therapy Methods Clin. Dev."},{"key":"10.1016\/j.msard.2025.106812_bib0004","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.msard.2019.06.030","article-title":"Plasma cell and B cell-targeted treatments for use in advanced multiple sclerosis","volume":"35","author":"Baker","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2025.106812_bib0005","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3390\/cells10051190","article-title":"B cell activation and escape of tolerance checkpoints: recent insights from studying autoreactive B cells","volume":"10","author":"Bonasia","year":"2021","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.msard.2025.106812_bib0006","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/ana.27029","article-title":"The role of chimeric antigen receptor T-cell therapy in immune-mediated neurological diseases","volume":"96","author":"Brittain","year":"2024","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106812_bib0007","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nature Rev. Clin. Oncol."},{"key":"10.1016\/j.msard.2025.106812_bib0008","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.coi.2012.12.003","article-title":"T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment","volume":"25","author":"Crespo","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.msard.2025.106812_bib0009","article-title":"Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression","volume":"358","author":"De","year":"2020","journal-title":"Cell Immunol."},{"key":"10.1016\/j.msard.2025.106812_bib0010","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jaci.2022.08.003","article-title":"New insights in systemic lupus erythematosus: from regulatory T cells to CAR-T-cell strategies","volume":"150","author":"Doglio","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.msard.2025.106812_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med."},{"key":"10.1016\/j.msard.2025.106812_bib0012","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J. Neuroinflammation."},{"issue":"1","key":"10.1016\/j.msard.2025.106812_bib0013","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12974-024-03262-w","article-title":"MOG-specific CAR tregs: a novel approach to treat multiple sclerosis","volume":"21","author":"Frikeche","year":"2024","journal-title":"J. Neuroinflammation."},{"key":"10.1016\/j.msard.2025.106812_bib0014","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/ejh.13380","article-title":"B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: a meta-analysis","volume":"104","author":"Gagelmann","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.msard.2025.106812_bib0015","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jtct.2022.03.006","article-title":"Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review","volume":"28","author":"Grant","year":"2022","journal-title":"TransPlant Cell Ther."},{"key":"10.1016\/j.msard.2025.106812_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102476","article-title":"Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee","volume":"69","author":"Greco","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.msard.2025.106812_bib0017","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200080","article-title":"CAR-T cell-mediated B-cell depletion in central nervous system autoimmunity","volume":"10","author":"Gupta","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"6","key":"10.1016\/j.msard.2025.106812_bib0018","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1474-4422(24)00140-6","article-title":"B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases","volume":"23","author":"Haghikia","year":"2024","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106812_bib0019","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/jamaneurol.2024.3818","article-title":"Current and future roles of chimeric antigen receptor T-cell therapy in neurology: a review","volume":"82","author":"Ismail","year":"2025","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2025.106812_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2025.106812_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.08.011","article-title":"Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis","volume":"175","author":"Jelcic","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.msard.2025.106812_bib0022","doi-asserted-by":"crossref","DOI":"10.1177\/08830738251335055","article-title":"Surviving grade 4 ICANS: a case report and discussion of emerging management strategies","author":"Jonokuchi","year":"2025","journal-title":"J. Child Neurol."},{"issue":"10","key":"10.1016\/j.msard.2025.106812_bib0023","doi-asserted-by":"crossref","first-page":"6526","DOI":"10.1007\/s00415-024-12642-4","article-title":"Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review","volume":"271","author":"Konitsioti","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106812_bib0024","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplan."},{"key":"10.1016\/j.msard.2025.106812_bib0025","doi-asserted-by":"crossref","first-page":"310ra166","DOI":"10.1126\/scitranslmed.aab4176","article-title":"Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy","volume":"7","author":"Li","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.msard.2025.106812_bib0026","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41582-023-00838-7","article-title":"Meningeal inflammation as a driver of cortical grey matter pathology and clinical progression in multiple sclerosis","volume":"19","author":"Magliozzi","year":"2023","journal-title":"Nature Rev. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2025.106812_bib0027","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/ajh.26915","article-title":"Clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance: 2023 update on clinical associations and management recommendations","volume":"98","author":"Mangaonkar","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.msard.2025.106812_bib0028","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/brain\/awab093","article-title":"Formation and immunomodulatory function of meningeal B-cell aggregates in progressive CNS autoimmunity","volume":"144","author":"Mitsd\u00f6rffer","year":"2021","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.msard.2025.106812_bib0029","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jcyt.2024.09.008","article-title":"Successful generation of fully human, second generation, anti-CD19 CAR T cells for clinical use in patients with diverse autoimmune disorders","volume":"27","author":"Mougiakakos","year":"2025","journal-title":"Cytotherapy."},{"key":"10.1016\/j.msard.2025.106812_bib0030","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-024-00470-5","article-title":"CAR-T therapy for multiple sclerosis enters US trials for first time","author":"Mullard","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.msard.2025.106812_bib0031","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1182\/blood-2022-171120","article-title":"CD19 CAR-T outcomes in patients with EBV-positive DLBCL","volume":"140","author":"Nair","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.msard.2025.106812_bib0032","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nature Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.msard.2025.106812_bib0033","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.ard.2025.03.018","article-title":"Relapse after anti-CD19 CAR T-cell therapy in a patient with severe rheumatoid arthritis and multiple sclerosis effectively treated by autologous stem cell transplantation","volume":"84","author":"Pecher","year":"2025","journal-title":"Ann. Rheum. Dis."},{"issue":"22","key":"10.1016\/j.msard.2025.106812_bib0034","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.3390\/diagnostics14222541","article-title":"Detection of brain-derived cell-free DNA in plasma","volume":"14","author":"Pellegrini","year":"2024","journal-title":"Diagnostics"},{"key":"10.1016\/j.msard.2025.106812_bib0036","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.msard.2025.106812_bib0037","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.msard.2025.106812_bib0038","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1182\/bloodadvances.2021006144","article-title":"Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment","volume":"6","author":"Schoeberl","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.msard.2025.106812_bib0039","doi-asserted-by":"crossref","first-page":"e1444","DOI":"10.1002\/cti2.1444","article-title":"Adoptive T-cell therapy targeting Epstein-Barr virus as a treatment for multiple sclerosis","volume":"12","author":"Smith","year":"2023","journal-title":"Clin. Transl. Immunol."},{"issue":"4","key":"10.1016\/j.msard.2025.106812_bib0040","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106812_bib0041","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/ard.2009.109041","article-title":"Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis","volume":"69","author":"Thurlings","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.msard.2025.106812_bib0042","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jamaneurol.2022.4655","article-title":"Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis","volume":"80","author":"Tur","year":"2023","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2025.106812_bib0043","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3389\/fimmu.2020.00760","article-title":"B and T cells driving multiple sclerosis: identity, mechanisms and potential triggers","volume":"11","author":"van Langelaar","year":"2020","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.msard.2025.106812_bib0044","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.msard.2025.106812_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103873","article-title":"CAR-macrophage: an extensive immune enhancer to fight cancer","volume":"76","author":"Wang","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2025.106812_bib0046","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin. Hematol."},{"issue":"4","key":"10.1016\/j.msard.2025.106812_bib0047","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMcibr2032177","article-title":"Antigen presentation by B cells in multiple sclerosis","volume":"384","author":"Zamvil","year":"2021","journal-title":"New England J. Med."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:36:27Z","timestamp":1784345787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825005541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":46,"alternative-id":["S2211034825005541"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106812","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR T cells for multiple sclerosis: Engineering T cells to disrupt chronic B cell\u2013driven neuroinflammation","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106812","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106812"}}